Tetracyclic indolines as a novel class of β-lactam-selective resistance-modifying agent for MRSA

Eur J Med Chem. 2017 Jan 5:125:130-142. doi: 10.1016/j.ejmech.2016.09.034. Epub 2016 Sep 10.

Abstract

Antibiotic-resistant bacterial infections have seen a marked increase in recent years, while antibiotic discovery has waned. Resistance-modifying agents (RMA) offer an intriguing alternative strategy to fight against resistant bacteria. Here we report the discovery, antibiotic profiling, and structure-activity relationships of a novel class of RMAs, tetracyclic indolines. These selectively potentiate β-lactam antibiotics in methicillin-resistant Staphylococcus aureus (MRSA) without antibacterial or β-lactamase inhibitory activity on their own. The most potent analogue, 6a, showed strong potentiation of amoxicillin/clavulanic acid in a variety of hospital-acquired and community-acquired MRSA strains with low mammalian toxicity. These compounds may be further developed to extend the clinic life span of β-lactam antibiotics.

Keywords: Antibiotic resistance; Indoline alkaloids; Methicillin-resistant Staphylococcus aureus; Resistance-modifying agent; Structure-activity relationship; β-lactam.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / microbiology
  • Drug Resistance, Bacterial / drug effects*
  • Drug Synergism
  • Humans
  • Indoles / pharmacology*
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Structure-Activity Relationship
  • Tetracyclines / pharmacology*
  • beta-Lactams / agonists*
  • beta-Lactams / metabolism

Substances

  • Anti-Bacterial Agents
  • Indoles
  • Tetracyclines
  • beta-Lactams
  • indoline